<DOC>
	<DOC>NCT00537914</DOC>
	<brief_summary>This study is performed to investigate the long-term safety, in particular the diabetogenic potential and immunogenicity of rhGH therapy in short children born small for gestational age (SGA).</brief_summary>
	<brief_title>Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)</brief_title>
	<detailed_description />
	<criteria>1. Prepubertal (Tanner stage I) children born SGA Boys: 4 years of age or older Girls: 4 years of age or older 2. Growth disturbance for chronological age and sex according to country specific references 3. Birth weight and/or length below 2 standard deviations (SD) for gestational age 1. Onset of puberty 2. Closed epiphyses 3. Diabetes mellitus type I or type II 4. Fasting blood glucose greater than 100 mg/dl or greater than 5.6 mmol/l measured in venous blood sample 5. Abnormal findings in Oral Glucose Tolerance Test (OGTT) defined by greater than 140 mg/dl or greater than 7.8 mmol/l after 120 minutes 6. Acute critical illness 7. Previous treatment with any hGH preparation 8. Treatment with antidiabetic medication (e.g. metformin, insulin) 9. Drug abuse, substance abuse, or alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Small for Gestational Age, Omnitrope®/Somatropin, rhGH,SGA</keyword>
</DOC>